Page 32 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 16 ฉบับที่ 3

366

∑’Ë¡’§«“¡‡¢â¡¢âπ√âÕ¬≈–‚¥¬¡«≈μàÕª√‘¡“μ√ 7.5 „π “√≈–≈“¬øÕ ‡øμ∫—ø‡øÕ√姫“¡‡¢â¡¢âπ 0.2

ª√‘¡“μ√ 20 ‰¡‚§√≈‘μ√ ∑‘È߉«â∑’ËÕÿ≥À¿Ÿ¡‘ÀâÕß ‡ªìπ‡«≈“ ¡‘≈≈‘‚¡≈“√å „ à≈ß„π 96 well plates À≈ÿ¡≈– ª√‘¡“μ√
30 π“∑’ ®“°π—Èπ𔉪«—¥§à“°“√¥Ÿ¥°≈◊π· ß∑’Ë 100 ‰¡‚§√≈‘μ√º ¡°—∫ “√≈–≈“¬ L-DOPA ∑’Ë

§«“¡¬“«§≈◊Ëπ 750 π“‚π‡¡μ√ π”§à“°“√¥Ÿ¥°≈◊𠧫“¡‡¢â¡¢âπ 2.5 ¡‘≈≈‘‚¡≈“√å ª√‘¡“μ√ 50 ‰¡‚§√≈‘μ√
· ß∑’ˉ¥â ‰ª§”π«≥À“ª√‘¡“≥ “√ª√–°Õ∫øïπÕ≈‘° ‡μ‘¡‡Õπ‰´¡å‰∑‚√´‘‡π ∑’˧«“¡‡¢â¡¢âπ 125 Àπ૬/
∑—ÈßÀ¡¥‡©≈’ˬ„π√Ÿª¡‘≈≈‘°√—¡¢Õß°√¥·°≈≈‘°μàÕ°√—¡ ¡‘≈≈‘≈‘μ√ ª√‘¡“μ√ 50 ‰¡‚§√≈‘μ√ º ¡„À⇢⓰—π

(¡‘≈≈‘°√—¡/°√—¡) ‡∑’¬∫®“°°√“ø¡“μ√∞“π√–À«à“ß ·≈–∫à¡∑’ËÕÿ≥À¿Ÿ¡‘ 37 Õß»“‡´≈‡´’¬ ‡ªìπ‡«≈“ 15 π“∑’
§«“¡‡¢â¡¢âπ¢Õß°√¥·°≈≈‘°·≈–§à“¥Ÿ¥°≈◊π· ß ®“°π—Èπ𔉪«—¥§à“°“√¥Ÿ¥°≈◊π· ß∑’Ë™à«ß§«“¡¬“«

‚¥¬∑”°“√∑¥ Õ∫μ—«Õ¬à“ß≈– 3 §√—Èß §≈◊Ëπ 490 π“‚π‡¡μ√ ¥â«¬‡§√◊ËÕß«—¥§à“°“√¥Ÿ¥°≈◊π
5.2 «‘‡§√“–À姫“¡ “¡“√∂„π°“√μâ“πÕπÿ¡Ÿ≈ · ß·∫∫‰¡‚§√‡æ≈∑ ∑”°“√§”π«≥√âÕ¬≈–°“√
[9]
Õ‘ √– (DPPH radical scavenging activity) ¬—∫¬—È߇Õπ‰´¡å‰∑‚√´‘‡π (%Inhibition) ¥—ß ¡°“√
‡μ√’¬¡ “√ °—¥‰À¡¢â“«‚楷≈– “√¡“μ√∞“π %Inhibition = (A - A )/ A x 100
§«∫§ÿ¡ ∑¥ Õ∫ §«∫§ÿ¡
α-Tocopherol (positive control) ∑’˧«“¡‡¢â¡¢âπ
7. °“√«‘‡§√“–Àå¢âÕ¡Ÿ≈
μ—Èß·μà 0-250 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ (Two-fold dilu-

tion) ≈–≈“¬„π‡Õ∑“πÕ≈ „ à≈ß„π 96 well plates °“√»÷°…“·μà≈–§√—Èß ∑”°“√∑¥≈Õß 3 ´È” π”§à“∑’Ë
À≈ÿ¡≈– 30 ‰¡‚§√¡‘≈≈‘≈‘μ√ ·≈â«‡μ‘¡ “√≈–≈“¬ ‰¥â¡“À“§à“∑“ß ∂‘μ‘ ‰¥â·°à §à“‡©≈’ˬ‡∫’ˬ߇∫π¡“μ√∞“π
DPPH ∑’Ë¡’§«“¡‡¢â¡¢âπ 0.5 ¡‘≈≈‘‚¡≈“√å ª√‘¡“μ√ 150 §à“§«“¡·ª√ª√«π ·≈–«‘‡§√“–À姫“¡·ª√ª√«π

‰¡‚§√≈‘μ√ ∑‘È߉«â∑’ËÕÿ≥À¿Ÿ¡‘ÀâÕß ‡ªìπ‡«≈“ 30 π“∑’ (Analysis of Variance: ANOVA) ∑’Ë√–¥—∫§«“¡
®“°π—Èπ𔉪«—¥§à“°“√¥Ÿ¥°≈◊π· ß∑’˧«“¡¬“«§≈◊Ë𠇙◊ËÕ¡—Ëπ 95 ‡ªÕ√凴Áπμå (p ≤ 0.05) ¥â«¬‚ª√·°√¡

595 π“‚π‡¡μ√ π”§à“∑’ˉ¥â‰ª§”π«≥√âÕ¬≈–°“√ ”‡√Á®√Ÿª Statistics Package for the Social Sci-
¬—∫¬—ÈßÕπÿ¡Ÿ≈Õ‘ √– DPPH (%inhibition) ¥—ß ¡°“√ ences (SPSS) version 17.0
·≈â«π”§à“§«“¡‡¢â¡¢âπ·≈–√âÕ¬≈–°“√¬—∫¬—ÈßÕπÿ¡Ÿ≈

Õ‘ √– DPPH‡æ◊ËÕÀ“§«“¡ —¡æ—π∏凙‘߇ âπ (y = ax + º≈°“√»÷°…“
2
b; r linear regression) ·≈–‡∑’¬∫À“§à“ IC %in-
50
1. º≈°“√‡μ√’¬¡ “√ °—¥‰À¡¢â“«‚æ¥
hibition = (A - A )/A x 100
§«∫§ÿ¡ “√ °—¥ §«∫§ÿ¡
æ∫«à“ “√ °—¥‰À¡¢â“«‚楄Àâ√âÕ¬≈–ª√‘¡“≥
[10]
6. °“√»÷°…“ƒ∑∏‘Ϭ—∫¬—È߇Õπ‰´¡å‰∑‚√´‘‡π
“√ °—¥·μ°μà“ß°—πÕ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘μ‘ (p =
«‘‡§√“–À姫“¡ “¡“√∂„π°“√¬—∫¬—È߇Õπ‰´¡å‰∑‚√ 0.01) ‚¥¬∑’ˉÀ¡¢â“«‚楢⓫‡À𒬫„Àâª√‘¡“≥ “√
´‘‡π (Tyrosinase inhibition activity) ‡μ√’¬¡ °—¥ Ÿß ÿ¥ √âÕ¬≈– 6.88 ± 0.02 √Õß≈ß¡“§◊Õ ‰À¡
“√ °—¥‰À¡¢â“«‚楷≈– “√¡“μ√∞“π°√¥‚§®‘° ¢â“«‚æ¥À«“π„Àâª√‘¡“≥ “√ °—¥ √âÕ¬≈– 6.44 ± 0.01

(positive control) ∑’˧«“¡‡¢â¡¢âπμ—Èß·μà 0-500 ·≈–‰À¡¢â“«‚æ¥À«“π ≈—∫ ’„Àâª√‘¡“≥ “√ °—¥μË” ÿ¥
‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ (Two-fold dilution) ≈–≈“¬ √âÕ¬≈– 4.23 ± 0.01 ¥—ßμ“√“ß∑’Ë 2